ANI Pharmaceuticals (ANIP) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvation Bio (NUVB) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 32.8% versus a loss of 21.5%. Over five years, ANIP leads with a +86.6% price change compared with -49.1% for NUVB. ANI Pharmaceuticals is the larger company by market cap ($1.64 billion vs $1.64 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | NUVB |
|---|---|---|
| Share price | $71.54 | $4.68 |
| Market cap | $1.64B | $1.64B |
| 1-day change | -0.55% | -3.81% |
| YTD return | -8.88% | -45.76% |
| 1-year return | -21.54% | +32.79% |
| 5-year return | +86.64% | -49.11% |
| P/E ratio (TTM) | 15.48 | — |
| Forward P/E | 7.04 | — |
| EPS (TTM) | $4.62 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $9.75 |
| 52-week low | $69.58 | $3.36 |
| Distance from 52-week high | -26.25% | -52.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +47.87% | +178.07% |
| Average volume | 372.56K | 5.65M |
| Shares outstanding | 22.96M | 350.12M |
| Employees | 970 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed ANIP by 54.3 percentage points over the past year.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
ANIP vs NUVB FAQ
Which is bigger, ANI Pharmaceuticals or Nuvation Bio?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.64B compared with $1.64B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, ANIP or NUVB?
NUVB returned +32.79% over the past 12 months, compared with -21.54% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.